Company Directory / research
PrivateFor profitresearchMorrisville, United States
Kriya Therapeutics
Kriya Therapeutics is a biopharmaceutical company that develops gene therapies for ophthalmology, neurology, and metabolic diseases.
- Founded
- 2019 7 years ago
- Staff
- 101-250 band, as listed
- Followers
- - on LinkedIn
- Funding
- $601M as listed, currency not stated
Set against six million companies
Size
101-250 people: larger than 85% of companies with a size listed
Age
7 years old.
Reach
Website ranked #4,799,291 in the world for traffic, about 2k visits a month.
What it does
BiotechnologyHealth CareLife Science
Funding, as listed
$601M currency not stated
- Rounds5
- LatestSeries c, Jul 2023
- Investors16, 3 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Kriya Therapeutics, field by field. Contact details are held but never shown.
The company
- Name
- Kriya Therapeutics
- Type
- For profit
- Status
- Private
- Founded
- 2019
- Founders
- Fraser Wright, Roger Jeffs, Shankar Ramaswamy
- Industry
- research
- Categories
- Biotechnology, Health Care, Life Science
Where
- City
- Morrisville
- Country
- United States
- Markets
- San Francisco Bay Area, Silicon Valley, West Coast, Western US
Size and reach
- Staff band
- 101-250
- Web traffic rank
- #4,799,291
- Monthly web visits
- 1,853
Funding, as listed
- Total
- 600,500,000 (currency not stated)
- Rounds
- 5
- Latest round
- Series c
- Latest round date
- Jul 2023
- Investors
- 16
- Lead investors
- 3
- Listing status
- private
Corporate family
- Acquisitions made
- 2
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Kriya Therapeutics may be growing as indicated by the unveiling of a new gene therapy product, KRIYA-586, which targets thyroid eye disease. This product launch suggests an expansion of the company's therapeutic portfolio. Additionally, the hiring of an experienced bioscience legal chief implies an investment in leadership and potentially a strategic move to navigate the complex legal landscape of biopharmaceuticals. While the articles do not provide direct financial numbers, these actions are typically associated with companies that are scaling up operations and investing in future capabilities.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
research in United States.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 1,637,054 companies in United States and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.